

# EXPANDING GLOBAL ACCESS TO CHRONIC HEPATITIS C TREATMENTS

It's Gilead's goal to give more people in more places access to treatments for chronic hepatitis C.


## A Profound Public Health Issue

THE WORLD HEALTH ORGANIZATION (WHO) ESTIMATES THAT OVER **170 MILLION PEOPLE** are infected worldwide.



## Stopping the Virus in Its Tracks

Scientific advances have led to the availability of direct acting antiviral treatment regimens that can cure\* most people with hepatitis C.



The WHO has now set a global target of treating

# 80%

OF ELIGIBLE PEOPLE WITH CHRONIC HEPATITIS C BY

# 2030

\*Cure, also known as sustained virologic response (SVR), is defined as no detectable hepatitis C virus in the blood at 12 or more weeks after therapy is complete.

## Access to Treatment Worldwide

Gilead employs a multi-pronged approach to make treatment more affordable to more of the world:



In the U.S., we offer discounts to insurance companies, co-pay support and **free treatment to qualified patients** through our access programs.



Internationally, we adjust prices through **a system of flexible, tiered pricing** based on a country's local economic conditions, as well as disease burden.




In nearly all low and lower-middle-income countries, we provide a flat **significantly discounted price** for our medicines.



## Enabling Generic Production

Gilead has licensed **generic MANUFACTURERS** to provide our medicines to **101** RESOURCE-CONSTRAINED COUNTRIES.



These countries are home to more than

# 100 million

 PEOPLE WITH CHRONIC HEPATITIS C VIRUS.

## Strengthening Local Health Systems

Gilead supports numerous in-country research, medical education and training programs to further knowledge and expertise of treating hepatitis C in resource-limited settings.



## Driving Research to Find New Cures



**GILEAD CONTINUES TO RESEARCH new treatment options TO BENEFIT PATIENTS WORLDWIDE.**

To learn more about our worldwide approach to increasing treatment access, visit [Gilead.com](http://Gilead.com)

Follow us on Twitter: @GileadSciences

